Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486859 | 1.00 | APLNR (0.34) | APLNRPOLBL3MBTL1ALDH1A1HPGD | |
| SCHEMBL25319330 | 1.00 | APLNR (0.34) | APLNRPOLBL3MBTL1ALDH1A1HPGD | |
| SCHEMBL16774688 | 0.83 | POLB (0.32) | POLBL3MBTL1 | |
| SCHEMBL21275078 | 0.81 | ALDH1A1 (0.30) | ALDH1A1HPGD | |
| SCHEMBL28195544 | 0.80 | TSHR (0.40) | POLBL3MBTL1 | |
| SCHEMBL15719269 | 0.79 | POLB (0.30) | POLBL3MBTL1 | |
| SCHEMBL21807485 | 0.77 | POLB (0.33) | POLBL3MBTL1 | |
| SCHEMBL15320412 | 0.77 | RIPK1 (0.42) | APLNRPOLBL3MBTL1 | |
| SCHEMBL25320199 | 0.77 | POLB (0.33) | POLBL3MBTL1 | |
| SCHEMBL21807487 | 0.77 | POLB (0.33) | POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860975-B1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3860975-A1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | Global Blood Therapeutics, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-11014884-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200140384-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
| WO-2020072377-A1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014884-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | APLNR 3829/4885POLB 3830/4885L3MBTL1 3699/4885 |
| US-20200140384-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | APLNR 3829/4885POLB 3830/4885L3MBTL1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.